drugset / Trial / NCT00360074

Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation

NCT00360074

Phase 4 Completed 25 enrolled University Hospital Freiburg
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to determine whether a body weight adjusted dose of thyroxin is superior to treatment guided by laboratory results of thyroxin hormones in patients with central hypothyroidism. Moreover beneficial effects of triiodthyronine supplementation are investigated.

Timeline

Start
2004-02
Primary completion
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Liothyronine Small molecule 0.16 ug/kg
Subject Thyroxin Unknown 1 ug/kg
Subject Thyroxin Unknown 1.44 ug/kg
Subject Thyroxin Unknown 1.6 ug/kg